ArticleBMC cancer2025
Novel prediction nomogram model for recurrent/persistent disease versus the American thyroid association recurrence risk stratification in patients with N1b papillary thyroid cancer: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Postoperative stimulated thyroglobulin and the ps-tg/TSH ratio enhance the 2025 ATA risk stratification for predicting radioiodine response in papillary thyroid carcinoma.Annals of medicine · 2026Article
- A seven-gene diagnostic and prognostic signature for papillary thyroid carcinoma.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPapillary thyroid carcinoma (PTC) is the most prevalent endocrine malignancy globally with a recurrence rate of up to 30%. Patients with lateral cervical metastasis (N1b PTC) are at a higher risk for reoperation. The aim of this study was to achieve a personalized assessment of recurrence risk in patients with N1b papillary thyroid carcinoma to better guide recurrence risk management.
methodsThis retrospective study included 558 patients with stage N1b papillary thyroid carcinoma. Independent risk factors for recurrence were identified using least absolute shrinkage and selection operator regression. These factors were used to develop a nomogram to predict the risk of recurrence.
resultsSeven variables were selected to construct the nomogram. The risk factors from the training set were used to develop the nomogram, which was validated with independent test sets. Recurrence risk was dynamically assessed over time, enabling the creation of more personalized treatment and monitoring plans. The nomogram provided more accurate and individualized recurrence predictions than the 2015 American Thyroid Association recurrence risk stratification for patients with N1b papillary thyroid carcinoma.
conclusionsOur nomogram effectively complements the 2015 American Thyroid Association recurrence risk stratification, providing a valuable tool for personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.